Oxidative stress in schizophrenia: An integrated approach

Oxidative stress has been suggested to contribute to the pathophysiology of schizophrenia. In particular, oxidative damage to lipids, proteins, and DNA as observed in schizophrenia is known to impair cell viability and function, which may subsequently account for the deteriorating course of the illness. Currently available evidence points towards an alteration in the activities of enzymatic and nonenzymatic antioxidant systems in schizophrenia. In fact, experimental models have demonstrated that oxidative stress induces behavioral and molecular anomalies strikingly similar to those observed in schizophrenia. These findings suggest that oxidative stress is intimately linked to a variety of pathophysiological processes, such as inflammation, oligodendrocyte abnormalities, mitochondrial dysfunction, hypoactive N-methyl-d-aspartate receptors and the impairment of fast-spiking gamma-aminobutyric acid interneurons. Such self-sustaining mechanisms may progressively worsen producing the functional and structural consequences associated with schizophrenia. Recent clinical studies have shown antioxidant treatment to be effective in ameliorating schizophrenic symptoms. Hence, identifying viable therapeutic strategies to tackle oxidative stress and the resulting physiological disturbances provide an exciting opportunity for the treatment and ultimately prevention of schizophrenia.

[1]  R. Mrak,et al.  Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. , 1996, Molecular and chemical neuropathology.

[2]  J. McGrath,et al.  Schizophrenia: a concise overview of incidence, prevalence, and mortality. , 2008, Epidemiologic reviews.

[3]  Trevor Archer,et al.  Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility , 2008, Pharmacology Biochemistry and Behavior.

[4]  D Saur,et al.  A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function , 2006, Molecular Psychiatry.

[5]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Fendri,et al.  Implication du stress oxydant dans la physiopathologie de la schizophrénie: revue de la littérature. , 2006 .

[7]  D. Javitt,et al.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.

[8]  E. Susser,et al.  In utero infection and adult schizophrenia. , 2002, Mental retardation and developmental disabilities research reviews.

[9]  B. Bogerts,et al.  Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia , 2001, Journal of neurocytology.

[10]  D. Matsuzawa,et al.  Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. , 2011, Antioxidants & redox signaling.

[11]  J. Hirrlinger,et al.  Peroxide detoxification by brain cells , 2005, Journal of neuroscience research.

[12]  N. Andreasen,et al.  The role of gender in studies of ventricle enlargement in schizophrenia: a predominantly male effect. , 1990, The American journal of psychiatry.

[13]  H. Monyer,et al.  NMDA receptor channels: Subunit-specific potentiation by reducing agents , 1994, Neuron.

[14]  Jeffrey K. Yao,et al.  Abnormal age-related changes of plasma antioxidant proteins in schizophrenia , 2000, Psychiatry Research.

[15]  Michael Berk,et al.  Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. , 2009, Annals of the Academy of Medicine, Singapore.

[16]  S. Mukherjee,et al.  Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.

[17]  Daniel R Weinberger,et al.  Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. , 2007, Human molecular genetics.

[18]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Horton,et al.  Lipid peroxidation and mechanisms of toxicity. , 1987, Critical reviews in toxicology.

[20]  B. Bogerts,et al.  Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics , 1998, Neuroscience.

[21]  S. Yehuda,et al.  Decrease of serum iron in acutely psychotic schizophrenic patients. , 1994, The International journal of neuroscience.

[22]  C. Wells,et al.  Disease-specific, neurosphere-derived cells as models for brain disorders , 2010, Disease Models & Mechanisms.

[23]  S. Oja,et al.  Release of [3H]GABA evoked by glutamate agonists from hippocampal slices: effects of dithiothreitol and glutathione , 1994, Neurochemistry International.

[24]  F. Wu,et al.  Kinetic studies on catechol O-methyltransferase. Product inhibition and the nature of the catechol binding site. , 1973, Biochemistry.

[25]  P. Guest,et al.  The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. , 2011, Antioxidants & redox signaling.

[26]  T. Nikolić,et al.  Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administration , 2010, Neuropharmacology.

[27]  H. Canatan,et al.  Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder , 2002, Cell biochemistry and function.

[28]  W. Bari,et al.  Zinc, Manganese, Calcium, Copper, and Cadmium Level in Scalp Hair Samples of Schizophrenic Patients , 2009, Biological Trace Element Research.

[29]  B. O'Shea,et al.  Smoking and Malignancy in Schizophrenia , 1984, British Journal of Psychiatry.

[30]  H. Canatan,et al.  Association between Ala–9Val polymorphism of Mn-SOD gene and schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  R. Murray,et al.  Early and late environmental risk factors for schizophrenia , 2000, Brain Research Reviews.

[32]  L. Ignarro,et al.  Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. , 1993, Journal of immunology.

[33]  K. Uğurbil,et al.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[34]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[35]  B. Nemeș,et al.  High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. , 2006, Life sciences.

[36]  Robert W McCarley,et al.  Gamma oscillation deficits and the onset and early progression of schizophrenia. , 2010, Harvard review of psychiatry.

[37]  F. Sharp,et al.  Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels , 1994, Neuroscience.

[38]  M. Mattson,et al.  4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes , 1997, Neuroscience.

[39]  H. Herken,et al.  The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. , 2002, Journal of psychiatric research.

[40]  L. Selemon,et al.  Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease. , 2001, Schizophrenia bulletin.

[41]  S. Fuchs,et al.  The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[43]  D. Javitt,et al.  Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. , 1998, Electroencephalography and clinical neurophysiology.

[44]  M. Dichter,et al.  Antioxidant Therapy in Neurologic Disease , 2000 .

[45]  Sandhya Mishra,et al.  Evaluation of antioxidant deficit in schizophrenia , 2008, Indian journal of psychiatry.

[46]  J. Guiramand,et al.  Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. , 2007, Free radical biology & medicine.

[47]  B. Ames,et al.  Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. , 2000, The Journal of nutrition.

[48]  Benjamin E. Deverman,et al.  Cytokines and CNS Development , 2009, Neuron.

[49]  H. Toyoda,et al.  Predominant contribution of IFN-beta expression to apoptosis induction in human uterine cervical fibroblast cells by influenza-virus infection. , 2004, Biological & pharmaceutical bulletin.

[50]  Vahram Haroutunian,et al.  Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia , 2007, Schizophrenia Research.

[51]  M. Ameloot,et al.  Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. , 2004, Journal of neuroscience research.

[52]  Eosu Kim,et al.  A Preliminary Investigation of &agr;-Lipoic Acid Treatment of Antipsychotic Drug-Induced Weight Gain in Patients With Schizophrenia , 2008, Journal of clinical psychopharmacology.

[53]  S. Mukherjee,et al.  Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.

[54]  I. Grattagliano,et al.  An update on the role of free radicals and antioxidant defense in human disease , 1999, International journal of clinical & laboratory research.

[55]  Y. Sun,et al.  Redox regulation of transcriptional activators. , 1996, Free radical biology & medicine.

[56]  M. Ameloot,et al.  Cytokine‐induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN‐γ and TNF‐α on apoptosis , 2004 .

[57]  S. J. Martin,et al.  Synaptic plasticity and memory: an evaluation of the hypothesis. , 2000, Annual review of neuroscience.

[58]  Kevin L Quick,et al.  Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase , 2007, Science.

[59]  E G Jones,et al.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[60]  G. Hanson,et al.  New insights into the mechanism of action of amphetamines. , 2007, Annual review of pharmacology and toxicology.

[61]  C. Behl,et al.  Antioxidants as treatment for neurodegenerative disorders , 2002, Expert opinion on investigational drugs.

[62]  D. Ferriero,et al.  Selective vulnerability in the developing central nervous system. , 2004, Pediatric neurology.

[63]  A. Ciobica,et al.  Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics , 2010, Neuroscience Letters.

[64]  S. Platt,et al.  The role of glutamate in central nervous system health and disease--a review. , 2007, Veterinary journal.

[65]  C. Palmer,et al.  A histochemical study of iron‐positive cells in the developing rat brain , 1995, The Journal of comparative neurology.

[66]  Cheuk Y. Tang,et al.  Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. , 2004, The American journal of psychiatry.

[67]  Karl J. Friston,et al.  Schizophrenia: a disconnection syndrome? , 1995, Clinical neuroscience.

[68]  Michael Berk,et al.  Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation , 2009, Neurobiology of Disease.

[69]  A. Roberts,et al.  IL-6 Mediated Degeneration of Forebrain GABAergic Interneurons and Cognitive Impairment in Aged Mice through Activation of Neuronal NADPH Oxidase , 2009, PloS one.

[70]  Yong-Ku Kim,et al.  Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls , 2008, Schizophrenia Research.

[71]  A. Aguilar-Valles,et al.  Prenatal Inflammation-Induced Hypoferremia Alters Dopamine Function in the Adult Offspring in Rat: Relevance for Schizophrenia , 2010, PloS one.

[72]  D. Goff,et al.  Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. , 1992, The American journal of psychiatry.

[73]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[74]  R. Reddy,et al.  Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[75]  A. Mackay-Sim,et al.  New techniques for biopsy and culture of human olfactory epithelial neurons. , 1998, Archives of otolaryngology--head & neck surgery.

[76]  A. Godzik,et al.  Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation , 2002, Trends in Neurosciences.

[77]  M. Lidow,et al.  Calcium signaling dysfunction in schizophrenia: a unifying approach , 2003, Brain Research Reviews.

[78]  H. Kornhuber,et al.  T-lymphocyte subpopulations in schizophrenic patients , 2005, European archives of psychiatry and neurological sciences.

[79]  S. Lipton,et al.  Redox modulation of the NMDA receptor , 2000, Cellular and Molecular Life Sciences CMLS.

[80]  S. Khanzode,et al.  Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia , 2005, Psychopharmacology.

[81]  D. Matsuzawa,et al.  A functional glutathione S‐transferase P1 gene polymorphism is associated with methamphetamine‐induced psychosis in Japanese population , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[82]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[83]  J. Gilmore,et al.  Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia , 1997, Schizophrenia Research.

[84]  P. Chan,et al.  Blockade of glutamate excitotoxicity and its clinical applications , 1993, Neurochemical Research.

[85]  T. Lockwood,et al.  Redox control of protein degradation. , 2000, Antioxidants & redox signaling.

[86]  G. Lenaz The Mitochondrial Production of Reactive Oxygen Species: Mechanisms and Implications in Human Pathology , 2001, IUBMB life.

[87]  H. Herken,et al.  Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.

[88]  D. Louis Collins,et al.  Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity , 2004, NeuroImage.

[89]  Alan S. Brown Prenatal Infection as a Risk Factor for Schizophrenia , 2008 .

[90]  Sheila E. J. Seybolt Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia? , 2010, Medical hypotheses.

[91]  M. Cuénod,et al.  N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial , 2008, Biological Psychiatry.

[92]  Steven Buyske,et al.  Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. , 2009, The American journal of psychiatry.

[93]  E. Klann,et al.  Reactive oxygen species in the regulation of synaptic plasticity and memory. , 2011, Antioxidants & redox signaling.

[94]  B. Pakkenberg,et al.  Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. , 1990, Archives of general psychiatry.

[95]  H. Tumani,et al.  Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders , 2009, Brain, Behavior, and Immunity.

[96]  G. Konat H2O2-induced higher order chromatin degradation: A novel mechanism of oxidative genotoxicity , 2003, Journal of Biosciences.

[97]  D. Dickson,et al.  Neuronal nitric oxide synthase expression in developing and adult human CNS. , 1999, Journal of neuropathology and experimental neurology.

[98]  M. Berk,et al.  Oxidative Stress in Psychiatric Disorders: Evidence Base and Therapeutic Implications , 2009 .

[99]  岡明 Vulnerability of Oligodendroglia to Glutamate: Pharmacology,Mechanisms,and Prevention(グルタミン酸によるオリゴデンドログリアの障害に関する研究 -その薬理学的解析および未熟児における脳室周囲軟化症の予防の可能性) , 1996 .

[100]  J J Kim,et al.  Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. , 1993, Archives of general psychiatry.

[101]  A. Glassman Cigarette smoking: implications for psychiatric illness. , 1993, The American journal of psychiatry.

[102]  C. Shaw,et al.  Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death , 1997, Brain Research Reviews.

[103]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[104]  J. Coward,et al.  Analogs of S-adenosylhomocysteine as potential inhibitors of biological transmethylation. Synthesis and biological activity of homocysteine derivatives bridged to adenine. , 1972, Journal of medicinal chemistry.

[105]  P. Emson,et al.  Expression of nNOS and soluble guanylate cyclase in schizophrenic brain , 2004, Neuroreport.

[106]  P. Seth,et al.  Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients , 2001, Psychopharmacology.

[107]  P. Ranjekar,et al.  Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients , 2003, Psychiatry Research.

[108]  D. Javitt,et al.  Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study , 1993, Biological Psychiatry.

[109]  A. Kerkeni,et al.  [Oxidative stress involvement in schizophrenia pathophysiology: a review]. , 2006, L'Encephale.

[110]  P. Goldman-Rakic,et al.  Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three‐dimensional, stereologic counting method , 1998, The Journal of comparative neurology.

[111]  Abraham Nyska,et al.  Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification , 2002, Toxicologic pathology.

[112]  D. Jackson,et al.  Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat , 1997, Psychopharmacology.

[113]  Jeffrey K. Yao,et al.  Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. , 2004, Schizophrenia bulletin.

[114]  T. Hastings Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[115]  W. Cammer,et al.  Maturation of oligodendrocytes is more sensitive to TNFα than is survival of precursors and immature oligodendrocytes , 1999, Journal of Neuroimmunology.

[116]  S. Hirsch,et al.  Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[117]  M. Cuénod,et al.  Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia , 2003, Schizophrenia Research.

[118]  P. Patterson Immune involvement in schizophrenia and autism: Etiology, pathology and animal models , 2009, Behavioural Brain Research.

[119]  O. Shirakawa,et al.  A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain , 2010, Schizophrenia Research.

[120]  E. Nestler,et al.  Epigenetics in the Nervous System , 2008, The Journal of Neuroscience.

[121]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[122]  J. Krystal,et al.  NMDA receptor regulation of memory and behavior in humans , 2001, Hippocampus.

[123]  A. Sawa,et al.  Nitric oxide signaling and nitrosative stress in neurons: role for S-nitrosylation. , 2011, Antioxidants & redox signaling.

[124]  A. Dasgupta,et al.  A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia , 2008, Indian journal of psychiatry.

[125]  Jeffrey K. Yao,et al.  Reduced status of plasma total antioxidant capacity in schizophrenia , 1998, Schizophrenia Research.

[126]  V. Nimgaonkar,et al.  Genetic association studies of antioxidant pathway genes and schizophrenia. , 2011, Antioxidants & redox signaling.

[127]  H. Nawa,et al.  Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models , 2010, Psychiatry and clinical neurosciences.

[128]  D. Nebert,et al.  Initial Characterization of the Glutamate-Cysteine Ligase Modifier Subunit Gclm(−/−) Knockout Mouse , 2002, The Journal of Biological Chemistry.

[129]  P. Kochanek,et al.  Effects of post‐injury hypothermia and nerve growth factor infusion on antioxidant enzyme activity in the rat: implications for clinical therapies , 2004, Journal of neurochemistry.

[130]  M. Segal,et al.  Hydrogen Peroxide Modulation of Synaptic Plasticity , 2003, The Journal of Neuroscience.

[131]  T. Werge,et al.  Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence , 2007, Proceedings of the National Academy of Sciences.

[132]  K. Iwamoto,et al.  Effect of a functional single nucleotide polymorphism in the 2′,3′‐cyclic nucleotide 3′‐phosphodiesterase gene on the expression of oligodendrocyte‐related genes in schizophrenia , 2008, Psychiatry and clinical neurosciences.

[133]  D. Braff,et al.  Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. , 2005, Archives of general psychiatry.

[134]  J. Loscalzo,et al.  Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.

[135]  D. Kammen,et al.  Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.

[136]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[137]  J. Kanner,et al.  Nitric oxide as an antioxidant. , 1991, Archives of biochemistry and biophysics.

[138]  Jeffrey K. Yao,et al.  Reduced level of plasma antioxidant uric acid in schizophrenia , 1998, Psychiatry Research.

[139]  D. Laifenfeld,et al.  Mitochondria, synaptic plasticity, and schizophrenia. , 2004, International review of neurobiology.

[140]  M. Cuénod,et al.  Skin fibroblast model to study an impaired glutathione synthesis: Consequences of a genetic polymorphism on the proteome , 2009, Brain Research Bulletin.

[141]  Bin Xu,et al.  Increased Expression in Dorsolateral Prefrontal Cortex of CAPON in Schizophrenia and Bipolar Disorder , 2005, PLoS medicine.

[142]  Y. Tochino,et al.  Methods for depleting brain glutathione. , 1989, Life sciences.

[143]  J. Suvisaari,et al.  Lifetime prevalence of psychotic and bipolar I disorders in a general population. , 2007, Archives of general psychiatry.

[144]  J. Kleinman,et al.  A postmortem quantitative study of iron in the globus pallidus of schizophrenic patients , 1990, Biological Psychiatry.

[145]  J. Kornhuber,et al.  Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients , 1994, Biological Psychiatry.

[146]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[147]  Ganesh Dakhale,et al.  Oxidative Damage and Schizophrenia: The Potential Benefit by Atypical Antipsychotics , 2004, Neuropsychobiology.

[148]  M. Cuénod,et al.  Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia , 2006, Neuroscience.

[149]  A. Sawa,et al.  Neuronal biomarkers from patients with mental illnesses: a novel method through nasal biopsy combined with laser-captured microdissection , 2010, Molecular Psychiatry.

[150]  S. Mukherjee,et al.  Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.

[151]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[152]  P. Flor-Henry Influence of gender in schizophrenia as related to other psychopathological syndromes. , 1990, Schizophrenia bulletin.

[153]  K. Takemasa,et al.  An event-related potential study on the impairment of automatic processing of auditory input in schizophrenia , 2005, Brain Topography.

[154]  M. Berk,et al.  eview athways underlying neuroprogression in bipolar disorder : Focus on nflammation , oxidative stress and neurotrophic factors , 2010 .

[155]  A. Vercesi,et al.  Mitochondrial damage induced by conditions of oxidative stress. , 1999, Free radical biology & medicine.

[156]  J. Connor,et al.  Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction. , 1994, Developmental neuroscience.

[157]  B. Carroll,et al.  Psychopathology and the brain , 1991 .

[158]  M. L. Genova,et al.  Mitochondrial Production of Oxygen Radical Species and the Role of Coenzyme Q as an Antioxidant , 2003, Experimental biology and medicine.

[159]  I. Pogribny,et al.  Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. , 2002, The Journal of nutrition.

[160]  V. Calabrese,et al.  Mitochondrial Involvement in Brain Function and Dysfunction: Relevance to Aging, Neurodegenerative Disorders and Longevity , 2001, Neurochemical Research.

[161]  M. Cuénod,et al.  Redox dysregulation, neurodevelopment, and schizophrenia , 2009, Current Opinion in Neurobiology.

[162]  F. Schenk,et al.  Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: Relevance to schizophrenia , 2007, Neurobiology of Disease.

[163]  N. Hayward,et al.  Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses , 2006, Schizophrenia Research.

[164]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[165]  T. Woo,et al.  Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia , 2008, Brain Research.

[166]  R. Reddy,et al.  Antioxidant therapeutics for schizophrenia. , 2011, Antioxidants & redox signaling.

[167]  X. Zhang,et al.  The Effect of Risperidone Treatment on Superoxide Dismutase in Schizophrenia , 2003, Journal of clinical psychopharmacology.

[168]  P. Goldman-Rakic,et al.  Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. , 1995, Archives of general psychiatry.

[169]  G. Kemmler,et al.  T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients , 1999, Schizophrenia Research.

[170]  H. Holcomb,et al.  Phenotype of schizophrenia: a review and formulation , 2005, Molecular Psychiatry.

[171]  D. Lewis,et al.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. , 2000, Archives of general psychiatry.

[172]  R. Dringen,et al.  Metabolism and functions of glutathione in brain , 2000, Progress in Neurobiology.

[173]  D. Ben-shachar,et al.  Increased mitochondrial complex I activity in platelets of schizophrenic patients. , 1999, The international journal of neuropsychopharmacology.

[174]  Robert O Wright,et al.  Metals and neurotoxicology. , 2007, The Journal of nutrition.

[175]  George Bartzokis,et al.  Schizophrenia: Breakdown in the Well-regulated Lifelong Process of Brain Development and Maturation , 2002, Neuropsychopharmacology.

[176]  M. Saadat,et al.  Genetic polymorphism of glutathione S-transferase T1: A candidate genetic modifier of individual susceptibility to schizophrenia , 2007, Psychiatry Research.

[177]  A. Chauhan,et al.  Oxidative stress in autism. , 2006, Pathophysiology : the official journal of the International Society for Pathophysiology.

[178]  J. Krystal,et al.  Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. , 2002, Archives of general psychiatry.

[179]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[180]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[181]  S. Andrews,et al.  Brain potential evidence for an auditory sensory memory deficit in schizophrenia. , 1995, The American journal of psychiatry.

[182]  H. Herken,et al.  Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia , 2007, Medical Principles and Practice.

[183]  D. Shalom Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. , 2002 .

[184]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[185]  T. Shinkai,et al.  Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia , 2002, Molecular Psychiatry.

[186]  Robert Freedman,et al.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers , 1997, Biological Psychiatry.

[187]  W. McGinnis Oxidative stress in autism. , 2004, Alternative therapies in health and medicine.

[188]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[189]  R. Floyd Antioxidants, oxidative stress, and degenerative neurological disorders. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[190]  Akira Sawa,et al.  Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1–ErbB4 and DISC1 , 2009, Trends in Neurosciences.

[191]  J. Cadet,et al.  Free radical mechanisms in schizophrenia and tardive dyskinesia , 1994, Neuroscience & Biobehavioral Reviews.

[192]  Lin He,et al.  A meta-analysis of oxidative stress markers in schizophrenia , 2010, Science China Life Sciences.

[193]  M. Berk,et al.  Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. , 2008, The international journal of neuropsychopharmacology.

[194]  R. Kahn,et al.  Sex differences in the risk of schizophrenia: evidence from meta-analysis. , 2003, Archives of general psychiatry.

[195]  A. Bassett,et al.  Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. , 2004, American journal of human genetics.

[196]  T. Kaneko,et al.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia , 2009, BMC psychiatry.

[197]  S. Rose,et al.  An inhibitor of nitric oxide synthesis prevents memory formation in the chick , 1992, Neuroscience Letters.

[198]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[199]  Zvulun Elazar,et al.  ROS, mitochondria and the regulation of autophagy. , 2007, Trends in cell biology.

[200]  J. Connor,et al.  Ferritin: a novel mechanism for delivery of iron to the brain and other organs. , 2007, American journal of physiology. Cell physiology.

[201]  K. Johnson,et al.  Nitric oxide induces neurotransmitter release from hippocampal slices. , 1992, European journal of pharmacology.

[202]  K. Davies Oxidative stress: the paradox of aerobic life. , 1995, Biochemical Society symposium.

[203]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[204]  A. Olsson,et al.  Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[205]  N. Uranova,et al.  The role of oligodendrocyte pathology in schizophrenia. , 2007, The international journal of neuropsychopharmacology.

[206]  J. Olney Excitatory amino acids and neuropsychiatrie disorders , 1989, Biological Psychiatry.

[207]  N. Andreasen,et al.  Sex differences in brain morphology in schizophrenia. , 1997, The American journal of psychiatry.

[208]  J. Houlé,et al.  NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: Application of laser microdissection technique , 2009, Journal of Neuroscience Methods.

[209]  Ravinder Reddy,et al.  Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.

[210]  S. M. Gibbs Regulation of neuronal proliferation and differentiation by nitric oxide , 2003, Molecular Neurobiology.

[211]  M. Behrens,et al.  Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia , 2008, The Journal of Neuroscience.

[212]  R. D. Schwartz,et al.  Bidirectional Modulation of GABA‐Gated Chloride Channels by Divalent Cations: Inhibition by Ca2+ and Enhancement by Mg2+ , 1994, Journal of neurochemistry.

[213]  F. Viteri,et al.  Iron and oxidative stress in pregnancy. , 2003, The Journal of nutrition.

[214]  Joseph J. Volpe,et al.  Maturation-Dependent Vulnerability of Oligodendrocytes to Oxidative Stress-Induced Death Caused by Glutathione Depletion , 1998, The Journal of Neuroscience.

[215]  B. Olas,et al.  Isoprostenes as indicators of oxidative stress in schizophrenia , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[216]  V. Arolt,et al.  Search for atypical lymphocytes in schizophrenia , 2004, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[217]  Ying Ma,et al.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study , 2006, Journal of Zhejiang University SCIENCE B.

[218]  W. Carpenter The deficit syndrome. , 1994, The American journal of psychiatry.

[219]  H. Canatan,et al.  Serum iron levels in schizophrenic patients with or without akathisia , 2003, European Neuropsychopharmacology.

[220]  E. Susser,et al.  Elevated prenatal homocysteine levels as a risk factor for schizophrenia. , 2007, Archives of general psychiatry.

[221]  G. Fenu,et al.  Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. , 2004, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[222]  H. Herken,et al.  Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia , 2004, Biological Trace Element Research.

[223]  Emmanuel Dias-Neto,et al.  Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation , 2009, BMC psychiatry.

[224]  R. Yoshimura,et al.  Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study , 2010, Human psychopharmacology.

[225]  S. Snyder,et al.  Signaling by Gasotransmitters , 2009, Science Signaling.

[226]  M. Berk,et al.  A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. , 2009, Current medicinal chemistry.

[227]  N. Vaziri,et al.  Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. , 2009, American journal of physiology. Renal physiology.

[228]  Joseph T. Coyle,et al.  The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.

[229]  B. Pearce,et al.  Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms , 2001, Molecular Psychiatry.

[230]  V. Arolt,et al.  Severe Tardive Dyskinesia in Affective Disorders: Treatment with Vitamin E and C , 2003, Neuropsychobiology.

[231]  M. Berk,et al.  N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility , 2008 .

[232]  R. Freedman,et al.  Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics , 1992, Biological Psychiatry.

[233]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[234]  R. Belmaker,et al.  Homocysteine levels in newly admitted schizophrenic patients. , 2004, Journal of psychiatric research.

[235]  K. Reinikainen,et al.  Do event-related potentials reveal the mechanism of the auditory sensory memory in the human brain? , 1989, Neuroscience Letters.

[236]  J. Gitlin,et al.  Copper and iron disorders of the brain. , 2007, Annual review of neuroscience.

[237]  R. McCreadie,et al.  The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects , 1995, British Journal of Psychiatry.

[238]  August G. Wang,et al.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. , 2006, American journal of human genetics.

[239]  A Correspondent in Cell Biology,et al.  Gene Regulation , 1967, Nature.

[240]  J. Volpe,et al.  Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[241]  A. Kerkeni,et al.  Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[242]  J. Truman,et al.  Nitric oxide-sensitive guanylate cyclase activity is associated with the maturational phase of neuronal development in insects. , 1996, Development.

[243]  D. Bredt,et al.  Synaptic signaling by nitric oxide , 1997, Current Opinion in Neurobiology.

[244]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[245]  A. Nappi,et al.  Iron, metalloenzymes and cytotoxic reactions. , 2000, Cellular and molecular biology.

[246]  M. Maziade,et al.  Male gender is associated with deficit schizophrenia: a meta-analysis , 2001, Schizophrenia Research.

[247]  A. Korten,et al.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. , 1992, Psychological medicine. Monograph supplement.

[248]  A. Contestabile,et al.  Roles of NMDA receptor activity and nitric oxide production in brain development , 2000, Brain Research Reviews.

[249]  Alan S. Brown,et al.  Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. , 2010, The American journal of psychiatry.

[250]  G. Buzsáki,et al.  Neuronal Oscillations in Cortical Networks , 2004, Science.

[251]  S. Fuchs,et al.  The α7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes , 2003 .

[252]  J. Engel,et al.  The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. , 2004, European journal of pharmacology.

[253]  S. Oja,et al.  Modulation of glutamate receptor functions by glutathione , 2000, Neurochemistry International.

[254]  E. Whitelaw,et al.  Epigenetic mechanisms in the context of complex diseases , 2007, Cellular and Molecular Life Sciences.

[255]  A. Chait,et al.  The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. , 1987, The Journal of biological chemistry.

[256]  X. Zhang,et al.  A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. , 2001, The Journal of clinical psychiatry.

[257]  X. Zhang,et al.  The Effect of Extract of Ginkgo Biloba Added to Haloperidol on Superoxide Dismutase in Inpatients With Chronic Schizophrenia , 2001, Journal of clinical psychopharmacology.

[258]  N. Uranova,et al.  Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium , 2004, Schizophrenia Research.

[259]  E. Klein,et al.  Mitochondrial complex i subunits expression is altered in schizophrenia: a postmortem study , 2004, Biological Psychiatry.

[260]  K. Do,et al.  New model of glutathione deficit during development: Effect on lipid peroxidation in the rat brain , 2002, Journal of neuroscience research.

[261]  T. Bártfai,et al.  A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons , 2006, The Journal of Neuroscience.

[262]  B. Jones,et al.  Lipid peroxidation and homocysteine induced toxicity. , 1994, Atherosclerosis.

[263]  Tamás F Freund,et al.  Interneuron Diversity series: Rhythm and mood in perisomatic inhibition , 2003, Trends in Neurosciences.

[264]  P. Somogyi,et al.  Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo , 2003, Nature.

[265]  Michael Berk,et al.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[266]  S Woolhandler,et al.  Smoking and mental illness: A population-based prevalence study. , 2000, JAMA.

[267]  L. Szweda,et al.  Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. , 1998, Biochemistry.

[268]  D. Lewis,et al.  Alterations of Cortical GABA Neurons and Network Oscillations in Schizophrenia , 2010, Current psychiatry reports.

[269]  N. Andreasen Schizophrenia: the fundamental questions , 2000, Brain Research Reviews.

[270]  Lin He,et al.  Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. , 2008, The international journal of neuropsychopharmacology.

[271]  C. Winterbourn Toxicity of iron and hydrogen peroxide: the Fenton reaction. , 1995, Toxicology letters.

[272]  M. Brand,et al.  Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. , 2003, Biochemical Society transactions.

[273]  Takayuki Obata,et al.  Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study , 2008, PloS one.

[274]  R. Yolken,et al.  Maternal Cytokine Levels during Pregnancy and Adult Psychosis , 2001, Brain, Behavior, and Immunity.

[275]  L. Qi,et al.  The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients , 2009, Schizophrenia Research.

[276]  J. Meador-Woodruff,et al.  Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder , 2008, Neuropsychopharmacology.

[277]  R. Huganir,et al.  Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. , 2005, American journal of human genetics.

[278]  W. Cammer Protection of cultured oligodendrocytes against tumor necrosis factor-α by the antioxidants coenzyme Q10 and N-acetyl cysteine , 2002, Brain Research Bulletin.

[279]  David A Lewis,et al.  Schizophrenia as a disorder of neurodevelopment. , 2002, Annual review of neuroscience.

[280]  S. Siris,et al.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1988, Archives of general psychiatry.

[281]  P. Ranjekar,et al.  Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia , 2003, Schizophrenia Research.

[282]  E. Suzuki,et al.  Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. , 2003, Journal of psychiatry & neuroscience : JPN.

[283]  Yan Shen,et al.  Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics , 2006, Schizophrenia Research.

[284]  T. Freund,et al.  Perisomatic Inhibition , 2007, Neuron.

[285]  G. Seaborg ROLE OF ENERGY , 1966 .

[286]  T. Woo,et al.  Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. , 2004, Archives of general psychiatry.

[287]  D. Butterfield,et al.  Redox regulation of cellular stress response in neurodegenerative disorders. , 2006, The Italian journal of biochemistry.

[288]  R. Kraftsik,et al.  Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors , 2010, The Journal of Neuroscience.

[289]  M. Cooke,et al.  Factors contributing to the outcome of oxidative damage to nucleic acids , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[290]  M. Smith,et al.  Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.

[291]  Mahmut Bulut,et al.  Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[292]  Michael Berk,et al.  Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice , 2009, Behavioural Brain Research.

[293]  J. Smythies The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion , 1999, Neurotoxicity Research.

[294]  Matcheri Keshavan,et al.  Reduced plasma antioxidants in first-episode patients with schizophrenia , 2003, Schizophrenia Research.

[295]  L. Hertz,et al.  Peroxide‐scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress , 1998, Glia.

[296]  Dean P. Jones,et al.  Superoxide in Apoptosis , 1998, The Journal of Biological Chemistry.

[297]  W. Cammer Apoptosis of oligodendrocytes in secondary cultures from neonatal rat brains , 2002, Neuroscience Letters.

[298]  M. Rathbone,et al.  Nitric oxide donors enhance neurotrophin‐induced neurite outgrowth through a cGMP‐dependent mechanism , 1997, Journal of neuroscience research.

[299]  S. Rozen,et al.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia , 2010, Molecular Psychiatry.

[300]  Karl J. Friston,et al.  Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.

[301]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[302]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[303]  E. Stadtman,et al.  Free radical-mediated oxidation of free amino acids and amino acid residues in proteins , 2003, Amino Acids.

[304]  T. Sejnowski,et al.  Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? , 2009, Neuropharmacology.

[305]  B. Freeman,et al.  Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. , 1991, Archives of biochemistry and biophysics.

[306]  M. Ikeda,et al.  No Association Between Polymorphisms of Neuronal Oxide Synthase 1 Gene (NOS1) and Schizophrenia in a Japanese Population , 2009, NeuroMolecular Medicine.

[307]  K. Krause,et al.  The NADPH Oxidase NOX2 Controls Glutamate Release: A Novel Mechanism Involved in Psychosis-Like Ketamine Responses , 2010, The Journal of Neuroscience.

[308]  Miles A Whittington,et al.  Interneuron Diversity series: Inhibitory interneurons and network oscillations in vitro , 2003, Trends in Neurosciences.

[309]  M. Berk,et al.  Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice , 2010, Pharmacology Biochemistry and Behavior.

[310]  C. Wass,et al.  The importance of nitric oxide in social dysfunction , 2009, Behavioural Brain Research.

[311]  D. Lorrain,et al.  Nitric oxide increases dopamine and serotonin release in the medial preoptic area , 1993, Neuroreport.

[312]  Jun-Feng Wang,et al.  Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. , 2011, The international journal of neuropsychopharmacology.

[313]  Elias S. J. Arnér,et al.  Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. , 2001, Free radical biology & medicine.

[314]  J. Coward,et al.  Inhibition of catechol-O-methyltransferase by S-adenosylhomocysteine and S-adenosylhomocysteine sulfoxide, a potential transition-state analog. , 1972, Biochemical pharmacology.

[315]  Jun-Feng Wang,et al.  Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. , 2010, Archives of general psychiatry.

[316]  J. Olney Excitatory amino acids and neuropsychiatric disorders. , 1989, Biological psychiatry.

[317]  S. Andrews,et al.  Mismatch negativity: An index of a preattentive processing deficit in schizophrenia , 1991, Biological Psychiatry.

[318]  Jeffrey K. Yao,et al.  An Overview of the Evidence and Its Therapeutic Implications , 2001 .

[319]  M. Owen,et al.  A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress , 2003, Schizophrenia Research.

[320]  C A Sandman,et al.  Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. , 1993, Archives of general psychiatry.

[321]  J. Feldon,et al.  A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. , 2009, Schizophrenia bulletin.

[322]  R. Buzina,et al.  Vitamin C status in chronic schizophrenia , 1990, Biological Psychiatry.

[323]  P. McKenna,et al.  Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms , 1996, PloS one.

[324]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[325]  E. Susser,et al.  Maternal iron deficiency and the risk of schizophrenia in offspring. , 2008, Archives of general psychiatry.

[326]  R. Kraftsik,et al.  Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. , 2011, Antioxidants & redox signaling.